BIO backs Fla. bill restricting biosimilar substitutions

04/5/2013 | Drug Store News

BIO praised a Florida Senate committee for passing a bill that would require pharmacists to notify physicians when a biosimilar drug was substituted for a brand-name biologic. S.B. 732 has a five-year sunset clause like the law signed in Virginia last month. "Biosimilars are not generics. Even slight changes to a biologic drug can change its properties entirely. Unlike conventional generic medicines, biosimilars are not the same as the drugs they seek to substitute," the BIO statement said.

View Full Article in:

Drug Store News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY